Tty Biopharm Co Stock Cash Flow From Operations
| 4105 Stock | TWD 74.90 0.60 0.79% |
TTY Biopharm Co fundamentals help investors to digest information that contributes to TTY Biopharm's financial success or failures. It also enables traders to predict the movement of TTY Stock. The fundamental analysis module provides a way to measure TTY Biopharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TTY Biopharm stock.
TTY |
TTY Biopharm Co Company Cash Flow From Operations Analysis
TTY Biopharm's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current TTY Biopharm Cash Flow From Operations | 1.26 B |
Most of TTY Biopharm's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TTY Biopharm Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, TTY Biopharm Co has 1.26 B in Cash Flow From Operations. This is 138.27% higher than that of the Healthcare sector and 241.16% higher than that of the Drug Manufacturers - Specialty & Generic industry. The cash flow from operations for all Taiwan stocks is 29.36% lower than that of the firm.
TTY Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TTY Biopharm's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of TTY Biopharm could also be used in its relative valuation, which is a method of valuing TTY Biopharm by comparing valuation metrics of similar companies.TTY Biopharm is currently under evaluation in cash flow from operations category among its peers.
TTY Fundamentals
| Return On Equity | 0.21 | |||
| Return On Asset | 0.0824 | |||
| Profit Margin | 0.24 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 20.05 B | |||
| Shares Outstanding | 248.65 M | |||
| Shares Owned By Insiders | 20.58 % | |||
| Shares Owned By Institutions | 17.40 % | |||
| Price To Earning | 13.04 X | |||
| Price To Book | 3.78 X | |||
| Price To Sales | 4.10 X | |||
| Revenue | 4.54 B | |||
| Gross Profit | 2.77 B | |||
| EBITDA | 1.27 B | |||
| Net Income | 831.89 M | |||
| Cash And Equivalents | 2.89 B | |||
| Cash Per Share | 11.63 X | |||
| Total Debt | 4.15 M | |||
| Debt To Equity | 19.30 % | |||
| Current Ratio | 2.73 X | |||
| Book Value Per Share | 21.97 X | |||
| Cash Flow From Operations | 1.26 B | |||
| Earnings Per Share | 4.79 X | |||
| Target Price | 75.0 | |||
| Number Of Employees | 31 | |||
| Beta | 0.35 | |||
| Market Capitalization | 19.37 B | |||
| Total Asset | 9.3 B | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 3.58 % | |||
| Net Asset | 9.3 B | |||
| Last Dividend Paid | 3.0 |
About TTY Biopharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze TTY Biopharm Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TTY Biopharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TTY Biopharm Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with TTY Biopharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TTY Biopharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TTY Biopharm will appreciate offsetting losses from the drop in the long position's value.Moving against TTY Stock
| 0.54 | 4746 | Formosa Laboratories | PairCorr |
| 0.42 | 4132 | Golden Biotechnology | PairCorr |
| 0.42 | 6409 | Voltronic Power Tech | PairCorr |
| 0.32 | 5274 | Aspeed Technology | PairCorr |
The ability to find closely correlated positions to TTY Biopharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TTY Biopharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TTY Biopharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TTY Biopharm Co to buy it.
The correlation of TTY Biopharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TTY Biopharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TTY Biopharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for TTY Biopharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for TTY Stock Analysis
When running TTY Biopharm's price analysis, check to measure TTY Biopharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TTY Biopharm is operating at the current time. Most of TTY Biopharm's value examination focuses on studying past and present price action to predict the probability of TTY Biopharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TTY Biopharm's price. Additionally, you may evaluate how the addition of TTY Biopharm to your portfolios can decrease your overall portfolio volatility.